Dengue antibody analysis center
Core D: Antibodyomics Core
This project looks at the kinds and actions of antibodies in people—especially children—who had dengue or dengue vaccines to learn when antibodies protect versus make illness worse.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-11111755 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers will use blood samples from children and adults who had dengue or received dengue vaccines to study their immune responses. They combine high-throughput antibody sequencing, single B cell sequencing that keeps natural antibody pairs, and antibody mass spectrometry to map which antibodies are present and what they do. Samples come from long-running pediatric dengue studies in Nicaragua, a vaccine group in the Philippines, and a U.S. vaccine challenge study. The goal is to create a detailed picture of antibody types, amounts, and functions after infection or vaccination.
Who could benefit from this research
Good fit: Ideal candidates are people who have had dengue infection, children enrolled in existing pediatric dengue cohorts, or people who received dengue vaccines and can provide blood samples.
Not a fit: People without any history of dengue exposure or those unwilling or unable to give blood samples are unlikely to directly benefit from participating.
Why it matters
Potential benefit: If successful, this work could help make safer, more effective dengue vaccines and tests by identifying which antibodies protect and which might increase risk.
How similar studies have performed: Antibody sequencing and mass-spectrometry approaches have worked well in other viral research, but combining these methods across long-term dengue cohorts is relatively new.
Where this research is happening
Berkeley, United States
- University of California Berkeley — Berkeley, United States (Active)
Researchers
- Principal investigator: Lavinder, Jason James — University of California Berkeley
- Study coordinator: Lavinder, Jason James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.